1,200 mg/m2/d for 2 days, leucovorin 400 mg/m2, oxaliplatin 85 mg/m2) × 12 cycles


Treatment received (specify dates, location, and providers):

Received FOLFOX from 11/10/04 to 04/13/05 at Northside Cancer Institute under the supervision of Dr. Jane Marks.


Unusual or unexpected toxicities during treatment:

None


Expected short- and long-term effects of treatment:

Sixth cycle held 1 week for thrombocytopenia, requiring a dose reduction in oxaliplatin to 65 mg/m2. Experienced cold-induced paresthesias in the hands and feet, but no residual neuropathy.


Late toxicity monitoring needed:

None


Surveillance needed for potential recurrence of cancer:

Clinical assessments and bloodwork including CEA every 3 months for 2 years, every 4 months for 1 year, then every 6 months for 2 years. After 5 years, either follow up on an as-needed basis or every 1–2 years, depending on patient choice.


Surveillance needed for second malignancies:

Colonoscopy 1 year after hemicolectomy. Subsequent schedule to depend on the findings. If not polyps or other disease, repeat every 3 to 5 years.


Physicians responsible for monitoring of toxicity, recurrence, second malignancies:

Dr. Jane Marks


Identified psychosocial issues or concerns:

Normal anxiety. Has contact with social worker, David Jones, as needed.


Recommended preventive behaviors, interventions, or genetic testing:

None specific for this cancer. Routine medical care recommended. Patient counseled regarding diet/nutrition. Patient given NCI booklet, Life After Cancer Treatment, and the NCCS “Cancer Survival Toolbox: An Audio Resource Program” that address medical and psychosocial issues, including those related to health insurance and employment.


NOTE: All individual and hospital names are fictitious.

SOURCE: Craig Earle, committee member, 2005.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement